Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia.

Trial Profile

Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 May 2015

At a glance

  • Drugs Ofatumumab (Primary) ; Dexamethasone
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 May 2015 Results published in the American Journal of Hematology.
    • 03 May 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 15 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top